ASCO Annual Meeting | Conference

Nivolumab/Ipilimumab Demonstrated Long-term Efficacy in Metastatic NSCLC

June 6th 2022

Results of a 5-year analysis of the phase 3 CheckMate 227 trial showed that the combination of nivolumab plus ipilimumab elicited durable overall survival benefit in patients with metastatic non–small cell lung cancer regardless of PD-L1 expression compared with chemotherapy.

Pathologic Response Is Key Indicator of EFS Benefit With Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC

June 6th 2022

Neoadjuvant nivolumab in combination with platinum-based doublet chemotherapy extended event-free survival in patients with stage IB-IIA non–small cell lung cancer who had pathologic complete response, according to a post hoc analysis of the phase 3 CheckMate 816 trial.

Capmatinib Plus Pembrolizumab Does Not Provide Clinical Benefit in MET Unselected, PD-L1-high Expressing NSCLC

June 6th 2022

The addition of the MET inhibitor capmatinib to pembrolizumab failed to improve clinical outcomes in patients with treatment-naïve non–small cell lung cancer with PD-L1 expression of at least 50% vs pembrolizumab alone, according to an analysis of outcomes of patients in the MET unselected population treated in a phase 2 trial.

Larotrectinib Shows Continued Tumor-Agnostic Efficacy in Pediatric TRK Fusion+ Cancer

June 6th 2022

Pediatric patients with non–central nervous system, TRK fusion–positive cancers who were enrolled to the phase 1/2 SCOUT and phase 2 NAVIGATE trials and received larotrectinib continued to experience rapid and durable tumor-agnostic efficacy and prolonged survival.

Dabrafenib Plus Trametinib Quadruples Response Rate in BRAF V600+ Pediatric Low-Grade Glioma

June 6th 2022

The combination of dabrafenib plus trametinib demonstrated a significant improvement in overall response rate, clinical benefit rate, and progression-free survival and fewer grade 3 or greater adverse effects and discontinuations vs carboplatin and vincristine in pediatric patients with low-grade glioma harboring a BRAF V600 mutation.

Nivolumab Plus Relatlimab Demonstrates Sustained PFS Benefit in Advanced Melanoma

June 6th 2022

Fixed-dose nivolumab plus relatlimab elicited continued progression-free survival benefit vs nivolumab alone in patients with treatment-naïve, unresectable or metastatic melanoma, according to updated results from the phase 2/3 RELATIVITY-047 trial.

Mobocertinib May Have Limited Intracranial Activity in EGFR Exon 20 Insertion+ NSCLC With Baseline Brain Mets

June 6th 2022

Mobocertinib may have limited intracranial activity in patients with EGFR exon 20 insertion–positive, non–small cell lung cancer with brain metastases at baseline, given the numerically lower response rate observed with the agent in this population.

Lurbinectedin Plus Pembrolizumab Produces Early Efficacy Signals in Relapsed Small Cell Lung Cancer

June 6th 2022

The combination of lurbinectedin and pembrolizumab demonstrated preliminary efficacy signals and was shown to be tolerable with a median relative dose intensity exceeding 90% in patients with small cell lung cancer that relapsed on platinum-based chemotherapy, according to findings from the phase 1/2 LUPER study.

Key Subgroup Analyses Supports Tafasitamab Plus Lenalidomide for High-Risk R/R DLBCL

June 6th 2022

Treatment with tafasitamab plus lenalidomide demonstrated trends toward improved overall survival vs systemic regimens across key subgroups of patients with high-risk relapsed or refractory diffuse large B-cell lymphoma who are not eligible for transplant, according to findings from an observational, retrospective analysis of the cohort RE-MIND2 study.

PSMA-PET Imaging Parameters Shown to Identify Optimal Population for 177Lu-PSMA-617 Treatment in mCRPC

June 6th 2022

68Ga-PSMA-11 PET/CT imaging parameters demonstrated a statistically significant association with clinical outcomes with the PSMA-targeted radioligand therapy lutetium-PSMA-617 in patients with metastatic castration-resistant prostate cancer.

Dr. Ansell on the Updated Analysis of ECHELON-1 in Classical Hodgkin Lymphoma

June 5th 2022

Stephen M. Ansell, MD, PhD, discusses the updated analysis of the phase 3 ECHELON-1 in classical Hodgkin lymphoma.

Dr. Shah on the Survival Analysis of Older Patients With B-Cell ALL in the ZUMA-3 Trial

June 5th 2022

Bijal D. Shah, MD, MS, discusses the survival analysis of subgroups of patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated in the phase 3 ZUMA-3 trial.

Tiragolumab and Atezolizumab Plus Chemotherapy Fails to Improve Survival Outcomes in Extensive-Stage SCLC

June 5th 2022

Tiragolumab combined with atezolizumab plus carboplatin and etoposide demonstrated no additional survival benefits compared with atezolizumab plus chemotherapy alone in patients with treatment-naïve, extensive-stage small cell lung cancer.

Larotrectinib Continues to Demonstrate High DCR, Elicit Durable Responses in TRK Fusion+ CNS Tumors

June 5th 2022

Larotrectinib continued to produce rapid and durable responses, with a high disease control rate and an acceptable toxicity profile in patients with TRK fusion–positive, primary central nervous system tumors.

Updated ENZAMET Data Underscore Long-term OS Benefit With Enzalutamide in mHSPC

June 5th 2022

The addition of enzalutamide vs a conventional nonsteroidal antiandrogen agent to testosterone suppression continued to provide clinically meaningful improvements in overall survival in patients with metastatic hormone-sensitive prostate cancer.

Adjuvant Pembrolizumab Results in Significant DMFS Improvement Over Placebo in Stage II Melanoma

June 5th 2022

Adjuvant pembrolizumab was found to result in a significant improvement in distant metastasis-free survival compared with placebo, with a continued reduction in risk of recurrence and an acceptable safety profile, in patients with resected stage IIB or stage IIC melanoma.

177Lu-PSMA-617 Provides Comparable OS Benefit to Cabazitaxel in mCRPC Progressing After Docetaxel

June 5th 2022

177Lu-PSMA-617 represents an acceptable option for patients with metastatic castration-resistant prostate cancer who are progressing after docetaxel, as it has been shown to provide similar overall survival benefit to that of cabazitaxel, with a stronger progression-free survival benefit and fewer toxicities

Ifosfamide Improves Survival vs Topotecan/Cyclophosphamide in R/R Ewing Sarcoma

June 5th 2022

Ifosfamide induced small improvements in terms of prolonging event-free survival and overall survival compared with topotecan plus cyclophosphamide in patients with relapsed/refractory Ewing sarcoma.

Larotrectinib Shows Sustained Efficacy, Safety Benefit in CNS TRK Fusion Cancer

June 5th 2022

Treatment with larotrectinib elicited robust and durable responses, had a favorable safety profile, and sustained survival benefit in patients with central nervous system TRK fusion cancers.

Selpercatinib Demonstrates Promising Activity in RET Fusion-Positive Solid Tumors

June 5th 2022

Extended follow-up data from the LIBRETTO-001 demonstrated that selpercatinib elicited durable responses in patients with RET fusion-positive solid tumors, including refractory gastrointestinal malignancies.